Prime Medicine, Financials
| PRME Etf | USD 2.00 0.05 2.56% |
Operating Margin | Short Ratio 17.29 | EPS Estimate Current Year (1.16) | EPS Estimate Current Quarter (0.31) | Return On Equity |
Prime |
The data published in Prime Medicine,'s official financial statements typically reflect Prime Medicine,'s business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Prime Medicine,'s quantitative information. For example, before you start analyzing numbers published by Prime accountants, it's essential to understand Prime Medicine,'s liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the presentation of Prime Medicine,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prime Medicine,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prime Medicine,'s management manipulating its earnings.
Prime Medicine, Etf Summary
Prime Medicine, competes with Beam Therapeutics, Caribou Biosciences, Intellia Therapeutics, Sana Biotechnology, and Ginkgo Bioworks. Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Etf View All |
| Exchange | NASDAQ Exchange |
| ISIN | US74168J1016 |
| CUSIP | 74168J101 |
| Region | Others |
| Investment Issuer | Others |
| Location | Massachusetts; U.S.A |
| Business Address | 60 First Street, |
| Etf Family | Biotechnology |
| Fund Category | Others |
| Portfolio Concentration | Others |
| Benchmark | Dow Jones Industrial |
| Website | primemedicine.com |
| Phone | 617 465 0013 |
| Currency | USD - US Dollar |
Prime Medicine, Key Financial Ratios
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.52 | ||||
| Target Price | 13.1 | ||||
| Number Of Employees | 214 | ||||
| Beta | 1.85 |
Prime Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Prime Medicine,'s current stock value. Our valuation model uses many indicators to compare Prime Medicine, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prime Medicine, competition to find correlations between indicators driving Prime Medicine,'s intrinsic value. More Info.Prime Medicine, Common is rated below average in price to earning as compared to similar ETFs. It also is rated below average in price to book as compared to similar ETFs fabricating about 0.12 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Prime Medicine, Common is roughly 8.65 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Prime Medicine, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Prime Medicine, Common Systematic Risk
Prime Medicine,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Prime Medicine, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Prime Medicine, Common correlated with the market. If Beta is less than 0 Prime Medicine, generally moves in the opposite direction as compared to the market. If Prime Medicine, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Prime Medicine, Common is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Prime Medicine, is generally in the same direction as the market. If Beta > 1 Prime Medicine, moves generally in the same direction as, but more than the movement of the benchmark.
Prime Medicine, March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Prime Medicine, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Prime Medicine, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Prime Medicine, Common based on widely used predictive technical indicators. In general, we focus on analyzing Prime Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Prime Medicine,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 25.37 | |||
| Value At Risk | (9.28) | |||
| Potential Upside | 10.03 |
Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.